Coronavirus disease 2019 (COVID-19) occurred in Wuhan, the capital city of Hubei Province, China, beginning in December 2019, and rapidly spread throughout China \[[@CIT0001]\]. The World Health Organization (WHO) has declared COVID-19 a public health emergency of international concern. Now, COVID-19 has become a global outbreak. Most of the published studies on COVID-19 have collected and analyzed clinical data from nonpregnant adults \[[@CIT0001]\]. To date, only a limited number of pregnant women with COVID-19 infection have been studied to investigate the possibility of intrauterine vertical transmission, and no evidence for intrauterine infection was found \[[@CIT0005], [@CIT0006]\].

Current knowledge and clinical management of pregnant women with COVID-19 is mainly based on information from the general population \[[@CIT0007]\]. In spite of the growing number of pregnant women with COVID-19, data on the clinical characteristics and disease severity of pregnant patients are still limited. Considering the particularity of immune status and physiological features in pregnant women, there is an urgent need to investigate the differences in the clinical characteristics and severity of COVID-19 between pregnant and nonpregnant women and the potential impact of COVID-19 infection on the clinical outcomes of the fetus and neonate. Answering these questions will be useful to the development of effective preventive and therapeutic strategies in clinical settings. Herein, we retrospectively and simultaneously identified clinical data from pregnant and childbearing-age nonpregnant women with laboratory-confirmed COVID-19 infection at Renmin Hospital in Wuhan University, Wuhan, China. In this study, we compare the detailed clinical characteristics of pregnant patients with nonpregnant patients, and we present the neonatal outcomes in pregnant patients.

METHODS {#s1}
=======

Study Design and Included Patients {#s2}
----------------------------------

First, we retrospectively reviewed the electronic medical records of patients with laboratory-confirmed COVID-19 admitted to Renmin Hospital of Wuhan University from January 15 to February 23, 2020. As previous studies have reported \[[@CIT0001]\], diagnosis of COVID-19 was based on the result of real-time reverse-transcriptase polymerase chain reaction (RT-PCR) of routine nasal and pharyngeal swab specimens or serum IgM and IgG antibody detection (≥10 AU/mL was defined as a positive result) using fully automatic chemical luminescence immunoanalysis technology per the manufacturer's instruction, according to the New Coronavirus Pneumonia Prevention and Control Program guidelines published by the National Health Commission of China \[[@CIT0008]\]. Female patients aged 22--41 years were included for further analysis. This study was approved by the Research Ethics Committee of Renmin Hospital of Wuhan University (approval number: WDRY2020-K076). Considering the urgent need for public health outbreak investigation, written informed consent was waived. All data were anonymously collected and analyzed. All studies and treatments administered were given as part of routine standard of care.

Data Collection {#s3}
---------------

Demographic, clinical, laboratory, and radiological parameters and treatment data including age, gestation, exposure history, coexisting disorders, signs, symptoms, chest computed tomography (CT) scans, and laboratory findings and treatments (eg, antiviral therapy, antibiotics/antifungal medication, systemic corticosteroid therapy, oxygen therapy, mechanical ventilation, kidney replacement therapy, extracorporeal membrane oxygenation) were identified from electronic medical records. Laboratory analyses included complete blood count, liver and renal function, electrolyte testing, coagulation function, C-reactive protein, procalcitonin, lactate dehydrogenase, myocardial enzymes, and cell and humoral immunity index. Inflammation indexes including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systematic inflammatory index (SII) were calculated using specific parameters of blood tests. NLR was defined as the absolute neutrophil count divided by the lymphocyte count. PLR was calculated by dividing the absolute platelet count by the lymphocyte count. SII was defined as platelet count × neutrophil count/lymphocyte count (/μL). Radiological analyses included x-ray and CT scans. Pregnant women who received CT scans signed written informed consent. For pregnant women, we collected neonatal outcomes, including gestational age at delivery, birthweight, Apgar score (1 minute, 5 minute), record of premature delivery, severe neonatal asphyxia, and neonatal death. A team of experienced obstetrician and gynecologists and respiratory physicians reviewed and extracted the data. Last follow-up was March 10, 2020.

Statistical Analysis {#s4}
--------------------

Categorical variables were expressed as the counts and percentages. Continuous variables were described as medians and interquartile range (IQR) values or simple ranges. Category variables were adopted using the chi-square test or Fisher exact test. Continuous variables were compared using independent group *t* tests or the Mann-Whitney test. All analyses were performed with the use of SPSS, version 20.0, and GraphPad Prism, version 6.0. For unadjusted comparisons, a 2-sided *P* \<.05 was considered statistically significant. Considering the possibility of type I error and analyses not adjusted for multiple comparisons, the results should be descriptively interpreted.

RESULTS {#s5}
=======

In total, 111 hospitalized childbearing-age women with laboratory-confirmed COVID-19 were included ([Table 1](#T1){ref-type="table"}). The median age (range) was 31.0 (22.0--41.0) years. Fifteen (13.5%) had coexisting disorders, including cardiovascular disease (5 \[4.5%\]), diabetes (4 \[3.6%\]), renal disease (2 \[1.8%\]), respiratory disease (1 \[0.9%\]), gastric ulcer (1 \[0.9%\]), mental sickness (1 \[0.9%\]), and malignancy (1 \[0.9%\]). Common symptoms included fever (64 \[57.7%\]), cough (62 \[55.9%\]), dyspnea (35 \[31.5%\]), asthenia (28 \[25.2%\]), and digestive tract symptoms (26 \[23.4%\]). Chest CT scans showed unilateral or bilateral abnormalities in the lungs of 103 (92.8%) patients, 5 patients with mild disease showed no abnormalities in both lungs (1 in the pregnant group and 4 in the nonpregnant group), and 3 pregnant patients refused the CT scan. Laboratory analyses ([Table 2](#T2){ref-type="table"}) showed that lymphopenia (lymphocyte count \[IQR\], 1.3 \[1.0--1.7\] ×10^9^/L) occurred in 36 patients (32.4%), neutropenia (neutrophil count \[IQR\], 2.9 \[2.0--4.8\] ×10^9^/L) in 24 patients (21.6%), hypoalbuminemia (41 \[37--43\] g/L) in 48 patients (43.2%), hypokalemia (3.9 \[3.6--4.2\] mmol/L) in 12 patients (10.8%), prolonged prothrombin time (11.5 \[11.0--12.0\] seconds) in 9 patients (8.1%), and elevated lactate dehydrogenase (189 \[160--223\] U/L) in 22 patients (19.8%). Mild disease emerged in 5 patients (4.5%), moderate disease in 90 patients (81.1%), severe disease in 12 patients (10.8%), and critical disease in 4 patients (3.6%) according to the New Coronavirus Pneumonia Prevention and Control Program guidelines (5th edition) published by the National Health Commission of China. Uncomplicated illness occurred in 5 patients (4.5%), mild pneumonia in 89 patients (80.2%), severe pneumonia in 12 patients (10.8%), and acute respiratory distress syndrome (ARDS) in 5 patients (4.5%) following the WHO guidelines for COVID-19. Most patients received antiviral therapy (104 \[93.7%\]), antibacterial therapy (89 \[80.2%\]), glucocorticoid therapy (41 \[36.9%\]), intravenous immune globulin (41 \[36.9%\]), and oxygen therapy (37 \[33.3%\]). One patient was transferred to the intensive care unit (ICU), and 1 received continuous renal replacement therapy ([Table 1](#T1){ref-type="table"}).

###### 

Clinical Characteristics of the Study Patients

                                                 Total (n = 111)     Pregnant (n = 31)   Nonpregnant (n = 80)   *P* Value
  ---------------------------------------------- ------------------- ------------------- ---------------------- -----------
  Age                                                                                                           
   Median (range), y                             32.0 (22.0--41.0)   29.0 (24.0--41.0)   33.0 (22.0--41.0)      .001
   Distribution, No. (%)                                                                                        
   22\~29 y                                      39 (35.1)           17 (54.8)           22 (27.5)              .007
   30\~39 y                                      63 (56.8)           13 (41.9)           50 (62.5)              .050
   40\~41 y                                      9 (8.1)             1 (3.2)             8 (10.0)               .432
  Gestation, No. (%)                                                                                            
   1\~13 wk (+6 d)                               5 (4.5)             5 (16.1)            /                      /
   14\~27 wk (+6 d)                              6 (5.4)             6 (19.4)            /                      /
   28\~40 wk                                     20 (18.0)           20 (64.5)           /                      /
  Coexisting disorders, No. (%)                                                                                 
   Cardiovascular diseases                       5 (4.5)             1 (3.2)             4 (5.0)                .916
   Respiratory diseases                          1 (0.9)             0 (0.0)             1 (1.3)                .621
   Diabetes                                      4 (3.6)             3 (9.7)             1 (1.3)                .117
   Malignancy                                    1 (0.9)             0 (0.0)             1 (1.3)                .621
   Renal diseases                                2 (1.8)             1 (3.2)             1 (1.3)                .926
   Gastric ulcer                                 1 (0.9)             0 (0.0)             1 (1.3)                .621
   Mental sickness                               1 (0.9)             1 (3.2)             0 (0.0)                .621
   Total                                         15 (13.5)           6 (19.4)            9 (11.3)               .263
  Signs and symptoms, No. (%)                                                                                   
   Fever on admission                            64 (57.7)           15 (48.4)           49 (61.3)              .219
   Cough                                         62 (55.9)           14 (45.2)           48 (60.0)              .158
   Nasal congestion                              2 (1.8)             0 (0.0)             2 (2.5)                .926
   Rhinorrhea                                    1 (0.9)             1 (3.2)             0 (0.0)                .621
   Sore throat                                   14 (12.6)           1 (3.2)             13 (16.3)              .125
   Myalgia or arthralgia                         9 (8.1)             1 (3.2)             8 (10.0)               .432
   Headache                                      2 (1.8)             0 (0.0)             2 (2.5)                .926
   Dizziness                                     3 (2.7)             0 (0.0)             3 (3.8)                .659
   Dyspnea                                       35 (31.5)           5 (16.1)            30 (37.5)              .030
   Asthenia                                      28 (25.2)           1 (3.2)             27 (33.8)              .002
   Digestive tract symptoms                      26 (23.4)           3 (9.7)             23 (28.8)              .060
   No symptoms                                   14 (12.6)           9 (29.0)            5 (6.3)                .001
   ≥3 symptoms                                   43 (38.7)           7 (22.6)            36 (45.0)              .030
  Abnormalities on chest CT, No. (%)                                                                            
   Normal                                        5 (4.5)             1 (3.2)             4 (5.0)                .067
   Unilateral                                    32 (28.8)           11 (35.5)           21 (26.3)              .335
   Bilateral                                     71 (64.0)           16 (51.6)           55 (68.8)              .092
   Not applicable                                3 (2.7)             3 (9.7)             0 (0.0)                .030
  Treatments                                                                                                    
   Antiviral medication, No. (%)                 104 (93.7)          29 (93.5)           75 (93.8)              .692
    Oseltamivir, No. (%)                         40 (36.0)           16 (51.6)           24 (30.0)              .033
    Arbidol, No. (%)                             92 (82.9)           25 (80.6)           67 (83.8)              .697
    Ribavirin, No. (%)                           22 (19.8)           8 (25.8)            14 (17.5)              .325
   Intravenous antibiotics, No. (%)              89 (80.2)           29 (93.5)           60 (75.0)              .053
   Antifungal medication, No. (%)                0 (0.0)             0 (0.0)             0 (0.0)                /
   Systemic glucocorticoids, No. (%)             41 (36.9)           20 (64.5)           21 (26.3)              \<.001
   Oxygen therapy, No. (%)                       37 (33.3)           2 (6.5)             35 (43.8)              \<.001
   Mechanical ventilation, No. (%)               0 (0.0)             0 (0.0)             0 (0.0)                /
    Invasive, No. (%)                            0 (0.0)             0 (0.0)             0 (0.0)                /
    Noninvasive, No. (%)                         0 (0.0)             0 (0.0)             0 (0.0)                /
   Use of ECMO, No. (%)                          0 (0.0)             0 (0.0)             0 (0.0)                /
   Use of intravenous immune globulin, No. (%)   41 (36.9)           7 (22.6)            34 (42.5)              .051
   Use of CRRT, No. (%)                          1 (0.9)             0 (0.0)             1 (1.3)                .621
   Admission to intensive care unit, No. (%)     1 (0.9)             0 (0.0)             1 (1.3)                .621

Abbreviations: CRRT, continuous renal replacement therapy; CT, computed tomography; ECMO, extracorporeal membrane oxygenation.

###### 

Laboratory Findings of the Study Patients

                                                                        Median (IQR)                                                            
  ----------------------------------------------------- --------------- ----------------------- ----------------------- ----------------------- --------
  Blood cell count                                                                                                                              
   White blood cell count, \*10^9^/L                    3.5--9.5        5.2 (3.8--7.2)          6.9 (5.6--9.1)          4.6 (3.5--6.1)          \<.001
   Lymphocyte count, \*10^9^/L                          1.1--3.2        1.3 (1.0--1.7)          1.1 (0.9--1.5)          1.3 (1.1--1.8)          .113
   Lymphocyte, %                                        20.0--50.0      28.4 (19.2--36.7)       18.2 (12.4--23.9)       31.8 (24.9--38.7)       \<.001
   White blood cell count---lymphocyte count, \*109/L   0.3--8.4        3.6 (2.6--5.6)          5.6 (4.1--8.0)          3.2 (2.2--4.3)          \<.001
   Neutrophil count, \*109/L                            1.8--6.3        2.9 (2.0--4.8)          5.2 (3.6--7.4)          2.5 (1.7--3.3)          \<.001
   Neutrophil, %                                        50.0--70.0      61.8 (52.4--72.4)       73.6 (68.5--81.9)       56.6 (50.1--65.2)       \<.001
   Platelet count, \*109/L                              125--350        205 (158--255)          180 (165--233)          213 (157--257)          .414
   Hemoglobin, g/L                                      115--150        125 (115--133)          120 (112--130)          127 (117--133)          .779
  Blood biochemical analysis                                                                                                                    
   C-reactive protein, mg/L                             \<10.0          2.5 (2.5--15.0)         8.8 (2.5--33.4)         2.5 (2.5--10.3)         .480
   Procalcitonin, ng/mL                                 \<0.10          0.034 (0.023--0.056)    0.068 (0.043--0.090)    0.03 (0.01--0.04)       .715
   Sodium, mmol/L                                       137--147        140 (139--144)          140 (137--144)          140 (139--143)          .610
   Potassium, mmol/L                                    3.5--5.3        3.9 (3.6--4.2)          3.9 (3.6--4.0)          4.0 (93.6--4.3)         .086
   Chloride, mmol/L                                     99--110         108 (105--109)          107 (105--109)          107 (105--109)          .324
   Albumin, g/L                                         40--55          41 (37--43)             37 (33--39)             41 (39--43)             \<.001
   Total bilirubin, μmol/L                              0--23           7.8 (6.0--10.3)         8.4 (7.3--11.9)         7.3 (5.6--9.4)          .624
   Alanine aminotransferase, U/L                        7--40           15.5 (10.8--22.0)       15.5 (11.0--24.3)       15.5 (10.0--20.8)       .411
   Aspartate aminotransferase, U/L                      13--35          19.5 (16.0--24.0)       21.0 (16.0--25.8)       19.0 (16.0--23.0)       .313
   Lactate dehydrogenase, U/L                           10--250         189 (160--223)          200 (181--254)          182 (152--218)          .311
   Blood urea nitrogen, mmol/L                          2.6--7.5        3.40 (2.76--4.03)       3.02 (2.41--3.40)       3.58 (2.94--4.28)       .138
   Creatinine, μmol/L                                   41--73          47.5 (42.0--53.0)       43.0 (37.3--49.8)       50.0 (44.0--53.0)       .380
   Creatine kinase-MB, ng/mL                            \<5.00          0.58 (0.43--0.73)       0.61 (0.35--1.12)       0.54 (0.45--0.67)       .531
   Myohemoglobin, μg/L                                  0--110          20 (14--28)             16 (11--29)             22 (16--28)             .356
   NT-pro B-type natriuretic peptide, pg/mL             0--450          30 (17--62)             45 (18--91)             22 (12--47)             .268
   Prothrombin time, sec                                9.0--13.0       11.5 (11.0--12.0)       11.0 (10.7--11.3)       11.7 (11.2--12.4)       \<.001
   Activated partial thromboplastin time, sec           25.0--31.3      28.2 (26.2--30.3)       27.8 (25.0--29.7)       28.2 (26.5--30.4)       .332
   Fibrinogen, g/L                                      2.00--4.00      3.64 (2.84--4.43)       4.43 (3.99--5.12)       3.10 (2.51--3.81)       \<.001
   D-dimer, mg/L                                        0.0--0.6        0.5 (0.2--1.4)          1.8 (0.8--3.3)          0.3 (0.2--0.5)          .015
   Fibrinogen degradation products, mg/L                0.00--5.00      1.49 (0.56--4.57)       5.15 (2.19--9.66)       0.70 (0.37--1.56)       .211
   Antithrombin-3, %                                    80.0--120.0     92.4 (82.6--99.9)       92.9 (82.3--102.9)      91.9 (83.1--97.6)       .329
  Cell immunity, \*109/L                                                                                                                        
   CD3+ cell %                                          56.0--86.0      74.9 (69.8--78.6)       76.7 (73.5--80.0)       73.7 (68.4--77.4)       .014
   CD3+ cell count                                      723.0--2737.0   858.0 (704.8--1131.0)   938.5 (741.5--1061.8)   845.0 (635.8--1138.5)   .717
   CD4+ cell %                                          33.0--58.0      40.3 (35.9--45.8)       39.7 (35.3--41.5)       41.1 (36.0--46.1)       .313
   CD4+ cell count                                      404.0--1612.0   477.5 (341.8--640.8)    463.0 (360.5--597.25)   481.0 (325.3--653.3)    .606
   CD8+ cell %                                          13.0--39.0      29.5 (23.8--34.2)       32.3 (26.6--38.0)       28.4 (22.3--32.4)       .003
   CD8+ cell count                                      220.0--1129.0   357.5 (233.0--458.8)    426.0 (344.3--465.3)    329.0 (228.3--452.5)    .079
   CD4+/CD8+ ratio                                      0.9--2.0        1.4 (1.1--1.8)          1.2 (0.9--1.6)          1.4 (1.1--2.0)          .023
   CD19+ cell %                                         5.0--22.0       12.2 (9.5--15.0)        10.3 (8.7--13.7)        12.7 (9.9--16.5)        .091
   CD19+ cell count                                     80.0--616.0     129.0 (96.3--185.5)     127.5 (94.0--163.3)     132.0 (96.5--209.0)     .324
   CD16+ CD56+ cell %                                   5.0--26.0       11.1 (7.9--14.9)        9.7 (7.8--14.8)         11.2 (8.2--14.8)        .244
   CD16+ CD56+ cell count                               84.0--724.0     123.0 (81.3--171.8)     123.0 (74.0--163.8)     123.0 (85.8--171.8)     .361
  Humoral immunity, g/L                                                                                                                         
   IgG                                                  7.0--16.0       11.35 (10.10--12.88)    9.76 (8.19--11.13)      11.90 (10.90--13.50)    \<.001
   IgM                                                  0.4--2.3        1.25 (0.91--1.56)       1.08 (0.90--1.44)       1.27 (0.92--1.71)       .170
   IgA                                                  0.7--4.0        2.01 (1.52--2.33)       1.83 (1.45--2.18)       2.05 (1.56--2.44)       .179
   IgE, IU/mL                                           \<100.0         34.7 (9.15--118.5)      29.9 (9.15--59.65)      37.7 (99.2--125.8)      .174
   C3                                                   0.9--1.8        1.0 (0.8--1.1)          1.1 (1.0--1.2)          0.9 (0.8--1.0)          \<.001
   C4                                                   0.1--0.4        0.2 (0.2--0.3)          0.2 (0.2--0.4)          0.2 (0.2--0.3)          .255

Abbreviation: IQR, interquartile range.

Thirty-one pregnant patients and 80 nonpregnant patients were included ([Table 1](#T1){ref-type="table"}). Compared with nonpregnant patients, pregnant patients were younger (median age, 29.0 vs 33.0 years; *P* \< .001), less likely to have dyspnea (5 \[16.1%\] vs 30 \[37.5%\]; *P* = .030), less likely to have asthenia (1 \[3.2%\] vs 27 \[33.8%\]; *P* = .002), and less symptomatic (≥3 symptoms: 7 \[22.6%\] vs 36 \[45.0%\]; *P* = .030; no symptoms: 9 \[29.0%\] vs 5 \[6.3%\]; *P* = .001). Respiratory rate (20/minute vs 20/minute; *P* = .248) ([Figure 1A](#F1){ref-type="fig"}) and oxygen saturation (95% vs 96%; *P* = .293) ([Figure 1A](#F1){ref-type="fig"}) at initial diagnosis were analogous between the 2 groups. Notably, pregnant patients had a significantly lower percentage of severe pneumonia and ARDS according to the WHO guidelines for COVID-19 (1 \[3.2%\] vs 16 \[14.4%\]; *P* = .001) ([Figure 1B](#F1){ref-type="fig"}) and severe or critical disease according to the Chinese COVID-19 guidelines (1 \[3.2%\] vs 15 \[18.8%\]; *P* = .002) ([Figure 1B](#F1){ref-type="fig"}), indicating a lower level of severity of COVID-19 in pregnant patients.

![Comparison of disease severity between pregnant and nonpregnant women with COVID-2019. A, Comparison of respiratory rate and oxygen saturation between P and NP women with COVID-2019. B, Comparison of disease severity classification between P and NP women with COVID-2019 according to World Health Organization guidelines for COVID-19 and Chinese guidelines for COVID-19. C, Comparison of NLR ratio, PLR ratio, and SII index at initial diagnosis between P and NP women with COVID-2019. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; NP, nonpregnant; P, pregnant; PLR, platelet-to-lymphocyte ratio; SII, systematic inflammatory index.](ofaa294f0001){#F1}

Laboratory analyses ([Table 2](#T2){ref-type="table"}) showed that pregnant patients had significantly higher white blood cell counts (6.9 vs 4.6 ×10^9^/L; *P* \< .001), neutrophil counts (5.2 vs 2.5 ×10^9^/L; *P* \< .001), higher levels of fibrinogen (4.43 vs 3.10 g/L; *P* \< .001), dramatically lower percentages of lymphocytes (18.2% vs 31.8%; *P* \< .001), lower levels of albumin (37 vs 41 g/L; *P* \< .001), and shorter prothrombin times (11.0 vs 11.7 seconds; *P* \< .001). Intriguingly, pregnant patients had substantially higher levels of inflammation markers including NLR ratio (4.4 vs 1.9; *P* \< .001) ([Figure 1C](#F1){ref-type="fig"}) and SII (812.8 vs 354.7; *P* \< .001) ([Figure 1C](#F1){ref-type="fig"}) but similar PLR ratios (150.9 vs 146.6; *P* = .831) ([Figure 1C](#F1){ref-type="fig"}) when compared with nonpregnant patients. In addition, cluster analysis of peripheral immune cells suggested that, in comparison with nonpregnant patients, pregnant patients had enhanced cell immunity with increased CD3+ cells (76.7% vs 73.7%; *P* = .014) ([Figure 2A](#F2){ref-type="fig"}), CD8+ cells (32.3% vs 28.4%; *P* = .003) ([Figure 2A](#F2){ref-type="fig"}), and C3 levels (1.1 vs 0.9 g/L; *P* \< .001) ([Figure 2B](#F2){ref-type="fig"}), but insufficient humoral immunity, with reduced CD4+/CD8+ ratios (1.2 vs 1.4; *P* = .023) ([Figure 2A](#F2){ref-type="fig"}) and IgG levels (9.76 vs 11.90 g/L; *P* \< .001) ([Figure 2B](#F2){ref-type="fig"}).

![Comparison of cell and humoral immunity between pregnant and nonpregnant women with COVID-2019. A, Comparison of the percentage of CD3+ cells, CD4+ cells and CD8+ cells, CD19+ cells, CD16+ CD56+ cells, and CD4+/CD8+ ratio at initial diagnosis between P and NP women with COVID-2019. B, Comparison of the level of IgG, IgM, IgA, IgE, C3, and C4 at initial diagnosis between P and NP women with COVID-2019. Abbreviations: NP, nonpregnant; P, pregnant.](ofaa294f0002){#F2}

Treatment options are summarized in [Table 1](#T1){ref-type="table"}. The percentages of pregnant patients who received oseltamivir (51.6% vs 30.0%; *P* = .033) and glucocorticoid (64.5% vs 26.3%; *P* \< .001) were significantly higher than in nonpregnant patients. The percentage of oxygen therapy was significantly lower in the pregnant group than the nonpregnant group (6.5% vs 43.8%; *P* \< .001). More nonpregnant patients received intravenous immune globulin than pregnant patients (42.5% vs 22.6%; *P* = .051), but the difference did not reach statistical significance. One patient was transferred to the ICU, and 1 received renal replacement therapy in the nonpregnant group. Only 1 patient had died in the nonpregnant group as of March 10, 2020.

Seventeen live births were recorded ([Table 3](#T3){ref-type="table"}). The median age of these puerperae (range) was 29 (24--34) years. The median body length (range) was 49 (45--52) cm, and the median birthweight (range) was 3120 (2300--3750) g. Only 1 premature neonate at 35 gestational weeks plus 6 days had a birthweight \<2500 g ([Table 3](#T3){ref-type="table"}). Seventeen live births had a median 1-minute Apgar score of 9 and a median 5-minute Apgar score of 10. One live birth had a 1-minute Apgar score of 7 and a 5-minute Apgar score of 9. All of live births had negative results of immediately postnatal COVID-19 detection. Two had positive results for COVID-19 2 days after birth mainly due to the contact transmission. Among these 2 live births, 1 had neonatal fever, and a CT scan showed viral pneumonia. After active treatment, she has totally recovered. No neonatal hypoglycemia, neonatal congenital malformation, severe neonatal asphyxia, or neonatal death was observed in these newborns ([Table 3](#T3){ref-type="table"}).

###### 

Neonatal Outcomes

  Patient ID                                   P1           P2           P3           P4       P5           P6           P7      P8       P9           P10          P11          P12          P13          P14          P15          P16          P17
  -------------------------------------------- ------------ ------------ ------------ -------- ------------ ------------ ------- -------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ --------
  Puerpera age, y                              29           32           34           29       26           24           33      31       28           27           26           30           28           31           29           33           29
  Gestational age at delivery                  37 wk, 1 d   39 wk, 1 d   37 wk, 6 d   36 wk    35 wk, 6 d   40 wk, 1 d   40 wk   41 wk    36 wk, 2 d   39 wk, 4 d   40 wk, 3 d   38 wk, 1 d   37 wk, 1 d   39 wk, 1 d   38 wk, 4 d   39 wk, 3 d   38 wk
  Premature delivery                           No           No           No           Yes      Yes          No           No      No       Yes          No           No           No           No           No           No           No           No
  Neonatal sex                                 Female       Female       Female       Female   Female       Female       Male    Female   Female       Female       Male         Male         Male         Female       Male         Male         Female
  Apgar score (1 min)                          9            9            9            9        9            9            9       9        9            9            9            9            9            9            7            9            9
  Apgar score (5 min)                          10           10           10           10       10           10           10      10       10           10           10           10           10           10           9            10           10
  Birthweight, g                               2890         3750         3400         2830     2300         3360         3450    3140     2900         2650         3680         3720         2940         3570         2650         3000         3120
  Neonatal body length                         49           51           50           46       50           50           52      48       48           49           52           51           49           50           47           49           45
  Neonatal congenital malformation             No           No           No           No       No           No           No      No       No           No           No           No           No           No           No           No           No
  Neonatal fever                               No           No           No           No       No           No           No      No       No           No           No           No           No           Yes          No           No           No
  Neonatal hypoglycemia                        No           No           No           No       No           No           No      No       No           No           No           No           No           No           No           No           No
  Severe neonatal asphyxia                     No           No           No           No       No           No           No      No       No           No           No           No           No           No           No           No           No
  Neonatal death                               No           No           No           No       No           No           No      No       No           No           No           No           No           No           No           No           No
  Postnatal admission to intensive care unit   No           No           No           No       No           No           No      No       No           No           No           No           No           No           No           No           No
  Postnatal mechanical ventilation             No           No           No           No       No           No           No      No       No           No           No           No           No           No           No           No           No

DISCUSSION {#s6}
==========

To our knowledge, this study is 1 of few case series of hospitalized childbearing-age female patients with laboratory-confirmed COVID-19. In comparison with nonpregnant patients, pregnant patients were less likely to have symptoms; had significantly higher white blood cell counts, neutrophil counts, fibrinogen and C3 levels, and percentages of CD3+ and CD8+ cells; had dramatically lower percentages of lymphocyte, albumin levels, CD4+/CD8+ ratios, and IgG levels; and had shorter prothrombin time. Of note, pregnant patients had a significantly lower percentage of severe disease according to both the WHO and Chinese COVID-19 guidelines and had a substantially higher level of inflammation markers including NLR ratio and SII than nonpregnant patients. In addition, 17 live births were recorded, all of which showed negative results for COVID-19 detection immediately postnatally, and none experienced severe comorbidities.

It is well known that the morbidity and mortality of viral pneumonia are higher in pregnant women compared with the general population when there is no effective antiviral therapy \[[@CIT0009], [@CIT0010]\]. The influenza epidemic of 1918 and the Asian flu epidemic of 1957 had a maternal mortality rate of 30%\~50% \[[@CIT0011]\]. For severe acute respiratory syndrome (SARS) due to SARS-coronavirus (CoV) infection in 2003, the case fatality rate of the pregnant cases was 25%. Fifty percent needed ICU admission, and 33% required endotracheal intubation, while in the present study the ICU admission rate was 17.5% (*P* = .012) and the intubation rate was 12.5% (*P* = .065) in the nonpregnant group \[[@CIT0010]\]. Pregnant women infected by Middle East respiratory syndrome coronavirus (MERS-CoV) had a case mortality as high as 40% \[[@CIT0009], [@CIT0012]\]. However, the current study showed that pregnant patients were less likely to have a severe or critical type of COVID-19 (3.2%) according to both the WHO and Chinese COVID-19 guidelines, which is significantly lower than the rate of 18.8% in nonpregnant women and also significantly lower than 15.7% in the whole population from a large-scale national analysis \[[@CIT0004]\]. Moreover, this national analysis reported lower rates of severe disease among women and younger patients than among men and older patients \[[@CIT0004]\]. Similarly, Chen et al. collected 118 pregnant women with COVID-19 and reported that the risk of severe disease compared favorably with the risk in general populations of patients with COVID-19, indicating no increased risk of severe disease among pregnant patients \[[@CIT0013]\]. Unlike influenza, SARS, and MERS-CoV, pregnant patients with COVID-19 were also less likely to have symptoms such as dyspnea, asthenia, and so on, suggesting that COVID-19 has distinct clinical features for pregnant women. Even though more pregnant patients received oseltamivir and glucocorticoid than the nonpregnant group, these is still no evidence that these 2 drugs could effectively inhibit SARS-CoV-2.

We also surveyed the distinct immunological features between pregnant and nonpregnant patients. In spite of a lower percentage of lymphocyte, pregnant patients had a substantially higher percentage of CD3+ and CD8+ cells, as well as inflammation markers including NLR, SII, and C3 level, when compared with nonpregnant patients. Previous studies together with the pathological examination found that cytokine release storm was the main cause of severe disease \[[@CIT0014]\]. Therefore, the different immunological features found in this study might contribute to the mild effect of COVID-19 in pregnant women. Furthermore, 14.4% of the females and 18.8% of nonpregnant women in our study were found to have severe disease, which is lower than the rates of 22.0%--31.6% of the total population in Wuhan city during the period of January to February 2020 \[[@CIT0001]\]. Consistently, previous studies have found that female patients with COVID-19 have a significantly lower rate of death and severe disease than male patients \[[@CIT0002]\]. COVID-19 infects the human body through binding angiotensin-converting enzyme II (ACE2), and ACE2 expression is significantly higher in men than women \[[@CIT0017]\]. Meanwhile, it has been reported that estrogen was a protective factor from severe pneumonia in animal models \[[@CIT0020], [@CIT0021]\]. Collectively, the unique immune and pathophysiological features found in this study might contribute to the finding that pregnant women are less likely to develop severe COVID-19 infection. Clarification of the related mechanisms might provide clues for the development of novel preventive or therapeutic strategies, as effective methods are still undetermined to overcome COVID-19 infection.

Among the 31 pregnant women, 17 live births were recorded, and all of these showed results negative for postnatal COVID-19 detection at the first testing, and 2 became positive thereafter, indicating that vertical transmission is rare. A case of a newborn infant who tested positive for COVID-19 at the Wuhan Children's Hospital in Hubei Province was reported on February 5, 2020, 30 hours following the infant's birth \[[@CIT0022]\], suggesting that strict quarantine is needed to prevent mother-to-child coronavirus transmission during delivery \[[@CIT0023]\]. As for the newborn infants in our study, all of them were live births with a normal Apgar score, and no severe neonatal asphyxia was observed. In contrast, a high incidence of preterm delivery, admission to the ICU, spontaneous abortion, and perinatal death have been reported in pregnant women with SARS \[[@CIT0022], [@CIT0024]\]. The discrepancy in obstetrical outcomes might be due to the severe hypoxia caused by SARS disease, while this was less likely to happen in pregnant women with COVID-19 in this study.

There are several limitations of this study that should be acknowledged. First, the sample size was relatively small, and the retrospective nature of this study will inevitably entail selection bias. Hence, we should cautiously interpret these findings, and large-scale, multicenter studies are still needed. Second, all of the included cases were from Wuhan; it would be better to collect patients in other cities of China, and even in other countries, to obtain a more comprehensive understanding of the clinical characteristics in pregnant and nonpregnant childbearing-age women with COVID-19. Third, because of the short follow-up period, a small portion of patients remained in the hospital. The potential impact of disease severity in pregnant and nonpregnant patients on clinical outcomes was not evaluated. Forth, data collection was clinically driven and was not systematic, so the findings should be descriptively interpreted. Given that COVID-19 is a novel infection, no systematic management protocols were in place, and the decision to perform certain laboratories or to administer certain treatments was the clinician's, and some therapies were not based on known efficacy/recommendations. Last but not least, clinical interpretation of laboratory comparisons between the pregnant and nonpregnant groups was limited by the inherent changes that occur in a normal pregnancy. The optimal comparisons would be conducted between mild/moderate and severe/critical disease groups in future investigations.

In conclusion, this single-center investigation involving 111 childbearing-age women with COVID-19 revealed that pregnant patients had a lower level of severity of COVID-19 together with an enhanced inflammatory response and cell immunity when compared with nonpregnant patients. These findings should provide useful information for understanding the pathogenesis and clinical course of pregnant patients with COVID-19 and will be helpful in the forumation of the principles of obstetric treatment for pregnant women with COVID-19 infection.
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